Loading
BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B.
CIViC holds 19 clinical evidence items and 0 assertions across 10 variants, naming Olaparib, Vorinostat, Valproic Acid and Everolimus and others. Open Targets scores its association with cancer at 0.88 (direct and indirect evidence; datatypes genetic literature 0.89, affected pathway 0.91, literature 0.99, genetic association 0.76, somatic mutation 0.94, animal model 0.38). IntOGen calls it a driver in 23 cohorts (3 activating, 20 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.
In plain words · BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1.
No product in this corpus aims at BAP1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA BAP1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining prostate cancer (5 of 11 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma, Mesothelioma, Biliary tract cancer (all types), Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Cervical cancer and more); Open Targets associates it with 7 specific cancer types at or above 0.5 (BAP1-related tumor predisposition syndrome, uveal melanoma, pleural mesothelioma, clear cell renal carcinoma, hereditary neoplastic syndrome, melanoma, uveal, susceptibility to, 2 and more). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q92560; CIViC gene BAP1; IntOGen BAP1; Human Protein Atlas BAP1 tissue; Open Targets ENSG00000163930 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Yoshimoto et al, 1996, "Biological functions of a novel human gene, hucep-6, which is specifically expressed in the central nervous system". Source.
Sources: HGNC HGNC:950 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92560 (protein name, function text, keywords and locations (REST API)); CIViC gene BAP1 (19 evidence items, 0 assertions, 10 variants; diseases: Malignant Mesothelioma, Clear Cell Renal Cell Carcinoma, Uveal Melanoma, Malignant Pleural Mesothelioma, Meningioma and 2 more (GraphQL API, CC0)); Open Targets ENSG00000163930 (association with cancer (MONDO_0004992) 0.88; per-cancer scores at or above 0.5: gastric cancer 0.54, hepatocellular carcinoma 0.53, cholangiocarcinoma 0.50, renal cell carcinoma 0.68, melanoma 0.82, malignant mesothelioma 0.68 (GraphQL API, CC0)); IntOGen BAP1 (driver in 23 cohorts (Act 3, LoF 20); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signalling, cell proliferation and cell viability. Antagonises PRC1 mediated H2AK119ub1 monoubiquitination. As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3. Location: Cytoplasm; Nucleus; Chromosome (UniProt). Locus 3p21.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Bone marrow, Colon, Duodenum, Endometrium, Epididymis and more.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BAP1" OR ABSTRACT:"BAP1" OR TITLE:"BRCA1 associated deubiquitinase 1" OR ABSTRACT:"BRCA1 associated deubiquitinase 1" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR TITLE:"hucep-6" OR ABSTRACT:"hucep-6" OR TITLE:"KIAA0272" OR ABSTRACT:"KIAA0272" OR TITLE:"UCHL2" OR ABSTRACT:"UCHL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BAP1, not a curated reading list.
Shares Mesothelioma, Biliary tract cancer (all types), Renal cell carcinoma, Oesophageal cancer.
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
Shares Mesothelioma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Biliary tract cancer (all types), Oesophageal cancer, CIViC, IntOGen.
Shares Mesothelioma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.